EDAP TMS S.A. (EDAP) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of EDAP TMS S.A. (NASDAQ:EDAP) from a strong sell rating to a hold rating in a research note released on Wednesday.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

EDAP has been the subject of a number of other reports. ValuEngine raised shares of EDAP TMS from a sell rating to a hold rating in a report on Friday, October 6th. HC Wainwright reaffirmed a buy rating and issued a $6.50 target price on shares of EDAP TMS in a report on Monday, October 9th.

Shares of EDAP TMS (NASDAQ EDAP) traded down 2.31% during trading on Wednesday, hitting $2.96. The company had a trading volume of 47,575 shares. EDAP TMS has a 52-week low of $2.25 and a 52-week high of $3.85. The stock’s 50-day moving average is $3.06 and its 200 day moving average is $2.96. The firm has a market capitalization of $85.83 million, a P/E ratio of 22.77 and a beta of 1.02.

EDAP TMS (NASDAQ:EDAP) last issued its earnings results on Wednesday, August 23rd. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.03). EDAP TMS had a negative net margin of 0.27% and a positive return on equity of 10.31%. The company had revenue of $10.40 million during the quarter, compared to analysts’ expectations of $10.00 million. During the same period last year, the business posted $0.10 earnings per share. The company’s quarterly revenue was up 13.0% on a year-over-year basis. Equities research analysts predict that EDAP TMS will post $0.01 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.com-unik.info/2017/10/29/edap-tms-s-a-edap-rating-increased-to-hold-at-zacks-investment-research.html.

Institutional investors have recently modified their holdings of the business. Archon Capital Management LLC purchased a new position in EDAP TMS in the second quarter valued at about $2,474,000. Essex Investment Management Co. LLC acquired a new stake in shares of EDAP TMS in the second quarter valued at approximately $172,000. Virtu KCG Holdings LLC acquired a new stake in shares of EDAP TMS in the second quarter valued at approximately $117,000. Finally, Hilton Capital Management LLC grew its position in shares of EDAP TMS by 43.1% in the second quarter. Hilton Capital Management LLC now owns 83,000 shares of the medical equipment provider’s stock valued at $274,000 after purchasing an additional 25,000 shares during the last quarter. 9.40% of the stock is owned by institutional investors.

About EDAP TMS

EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.

Get a free copy of the Zacks research report on EDAP TMS (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about EDAP TMS S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for EDAP TMS S.A. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit